Furthermore, SOX2 is overexpressed and associated with poor prognosis in almost all human cancer types; it is considered to be a key regulator of tumorigenicity, drug resistance, and metastasis in a variety of tumors, including cancers of the ovary, lung, skin, brain, breast, prostate, and pancreas [12, 13]. This evidence concerns the gene SOX2 and ovarian cancer.